MedTrace Logo

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-05-21

No results posted yet for this study

Summary

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.

Conditions

  • Venous Thrombosis

Interventions

BIOLOGICAL

MK-2060

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

BIOLOGICAL

Placebo

Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2025-04-18
Completion
2025-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582602 on ClinicalTrials.gov